Nathan Pennell, MD, PhD
Dr. Pennell is a board-certified medical oncologist who has spent more than two decades in clinical practice, specializing in the treatment of thoracic malignancies, including pleural mesothelioma and lung cancer. He is now a Senior Vice President and head of Global Medical Oncology for Bristol Myers Squibb.[1]
Education and Career
After graduating from the University of North Carolina at Chapel Hill with a Bachelor of Science in Biology, Dr. Pennell pursued a Ph.D. in neuroscience and earned a medical school degree at the University of Florida College of Medicine.
He completed a residency in Internal Medicine at Brigham and Women’s Hospital in Boston and his medical oncology fellowship training at the Dana Farber Cancer Institute.[1]
After serving as Assistant Professor of Medicine at Massachusetts General Hospital, Dr. Pennell joined the Cleveland Clinic, where he was Vice Chair of Clinical Research and Director of the Taussig Cancer Institute’s Lung Cancer Medical Oncology Program.
He was also a Professor in the Department of Medicine of the Case Western University School of Medicine and a Member of the Immune Oncology Program at the Case Comprehensive Cancer Center.
Dr. Pennell is now a Senior Vice President at Bristol Myers Squibb, where he leads Global Medical Oncology. He helps the company work towards treatments that improve patient outcomes. As a thoracic oncologist, Dr. Pennell’s interests and expertise focused on lung cancer.
Dr. Pennell is interested in healthcare information technology and social media. He is a past Consultant Editor for the Journal of Oncology Practice, is Associate Editor of the American Society of Clinical Oncology (ASCO) Education Book, and has been featured as one of ASCO’s “Featured Voices” on Twitter for the group’s annual meeting.
Research Interests
Dr. Pennell’s research interests have included clinical trials using novel therapies like immunotherapy to facilitate the movement of new treatments from the laboratory to the clinic.
He is currently interested in the design of clinical trials, biomarker-driven therapy, lung cancer sequencing strategies, and precision oncology. He is dedicated to using science to improve patient outcomes.
